Investment analysts at StockNews.com started coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a report issued on Thursday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance
The stock has a market cap of $6,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.61. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24. Genocea Biosciences has a 1 year low of $0.00 and a 1 year high of $0.00.
Genocea Biosciences Company Profile
Featured Articles
- Five stocks we like better than Genocea Biosciences
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- How to Start Investing in Real Estate
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.